Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2024

Conditions
Recurrent Ovarian Carcinoma
Interventions
DRUG

Placebo

Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1

DRUG

Carboplatin

Intravenous. Day 1

DRUG

Paclitaxel

175 mg/m². Intravenous. Day 1

DRUG

Niraparib

200 mg or 300 mg. Oral. From day 1 to 21

DRUG

Gemcitabine

1000 mg/m². Intravenous. Day 1 and day 8.

DRUG

Pegylated liposomal doxorubicin (PLD)

30 mg/m². Intravenous. Day 1

DRUG

Atezolizumab

1200 mg. Intravenous. Day 1

Trial Locations (71)

13009

Institut Paoli Calmettes, Marseille

14000

Centre François Baclesse, Caen

22198

HPCA Cario, Plérin

25000

CHU Besançon, Besançon

30900

ONCOGARD - Institut de Cancérologie du Gard, Nîmes

31008

Clinica Universidad de Navarra, Pamplona

33000

Institut Bergonié, Bordeaux

34298

ICM Val d'Aurelle, Montpellier

44800

ICO Centre René Gauducheau, Saint-Herblain

49055

ICO - Paul Paupin - ANGERS, Angers

54519

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

63011

Centre Jean Perrin, Clermont-Ferrand

68167

Universitätsklinikum Mannheim, Mannheim

69008

Centre Léon Bérard, Lyon

75014

Hôpital Cochin, Paris

75015

Hôpital Européen Georges Pompidou, Paris

75020

Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris

Hôpital Tenon, Paris

92210

Institut Curie - Hopital Claudius Régaud, Saint-Cloud

Institut Curie - Hôpital René Huguenin- SAINT CLOUD, Saint-Cloud

94800

Gustave Roussy, Villejuif

Unknown

Grand Hôpital de Charleroi, Charleroi

UZ Leuven, Leuven

CHU de Liège, site Sart Tilman, Liège

CHU Ambroise Paré, Mons

CHU UCL Namur site St. Elisabeth, Namur

Hochtaunus-Kliniken, Bad Homburg

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

Kliniken Essen-Mitte, Essen

Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg

Diakovere Krankenhaus, Hanover

Klinikum Kulmbach, Kulmbach

Universitätsklinikum Münster, Münster

MVZ Nordhausen, Nordhausen

Klinikum Oldenburg AöR, Oldenburg

ROMed Klinikum Rosenheim, Rosenheim

Universitätsklinikum Tübingen, Tübingen

Universitätsfrauenklinik Ulm, Ulm

HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden

Spedali Civili, Brescia

Asst Lecco, Lecco

Istituto Europeo di Oncologia, Milan

I.R.C.C.S. Istituto Oncologico Veneto, Padua

Arcispedale Santa Maria Nuova, Reggio Emilia

AO Città della Salute e della Scienza- Ospedale Sant'Anna, Torino

Ospedale Mauriziano Umberto I, Torino

Hospital de Sabadell, Sabadell

Complejo Hospitalario Universitario de A Coruña, A Coruña

ICO Badalona, Badalona

H. Clínic Barcelona, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital de la Vall d'Hebron, Barcelona

H Reina Sofía Cordoba, Córdoba

ICO Girona, Girona

ICO Hospitalet, Hospitalet Del Llobregat

Hospital de León, León

Clinica Universitaria de Navarra, Madrid

Hospital Clínico San Carlos, Madrid

Hospital Gregorio Marañon, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Complejo Hospitalario Regional de Málaga, Málaga

H Morales Meseguer, Murcia

Hospital Son Llatzer, Palma de Mallorca

Hospital Virgen del Rocio, Seville

H La Fe de Valencia, Valencia

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitario Miguel Servet, Zaragoza

06100

Centre Antoine Lacassagne, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

AGO Study Group

OTHER

collaborator

Belgian Gynaecological Oncology Group

OTHER

collaborator

ARCAGY/ GINECO GROUP

OTHER

collaborator

Israeli Society of Gynecologic Oncology

OTHER

collaborator

MaNGO

UNKNOWN

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Grupo Español de Investigación en Cáncer de Ovario

OTHER